Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 3
1962 2
1963 2
1966 2
1967 2
1968 2
1969 2
1971 2
1975 4
1976 3
1978 4
1979 5
1980 3
1981 8
1982 5
1983 6
1984 9
1985 2
1986 4
1987 7
1988 12
1989 6
1990 9
1991 7
1992 5
1993 5
1994 7
1995 5
1996 3
1997 4
1998 5
1999 7
2000 4
2001 7
2002 2
2003 5
2004 3
2005 4
2006 3
2007 6
2008 3
2009 2
2010 5
2011 12
2012 6
2013 6
2014 4
2015 10
2016 8
2017 11
2018 11
2019 11
2020 11
2021 12
Text availability
Article attribute
Article type
Publication date

Search Results

286 results
Results by year
Filters applied: . Clear all
Page 1
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Kudo M, et al. Among authors: tamai t. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. Lancet. 2018. PMID: 29433850 Free article. Clinical Trial.
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. Yamashita T, et al. Among authors: tamai t. J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12. J Gastroenterol. 2020. PMID: 31720835 Free PMC article. Clinical Trial.
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H. Ikeda K, et al. Among authors: tamai t. J Gastroenterol. 2017 Apr;52(4):512-519. doi: 10.1007/s00535-016-1263-4. Epub 2016 Oct 4. J Gastroenterol. 2017. PMID: 27704266 Free PMC article. Clinical Trial.
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: tamai t. Oncology. 2019;97(5):277-285. doi: 10.1159/000501281. Epub 2019 Jul 15. Oncology. 2019. PMID: 31307035
Seasonal changes in NRF2 antioxidant pathway regulates winter depression-like behavior.
Nakayama T, Okimura K, Shen J, Guh YJ, Tamai TK, Shimada A, Minou S, Okushi Y, Shimmura T, Furukawa Y, Kadofusa N, Sato A, Nishimura T, Tanaka M, Nakayama K, Shiina N, Yamamoto N, Loudon AS, Nishiwaki-Ohkawa T, Shinomiya A, Nabeshima T, Nakane Y, Yoshimura T. Nakayama T, et al. Among authors: tamai tk. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9594-9603. doi: 10.1073/pnas.2000278117. Epub 2020 Apr 10. Proc Natl Acad Sci U S A. 2020. PMID: 32277035 Free PMC article.
Identification of circadian clock modulators from existing drugs.
Tamai TK, Nakane Y, Ota W, Kobayashi A, Ishiguro M, Kadofusa N, Ikegami K, Yagita K, Shigeyoshi Y, Sudo M, Nishiwaki-Ohkawa T, Sato A, Yoshimura T. Tamai TK, et al. EMBO Mol Med. 2018 May;10(5):e8724. doi: 10.15252/emmm.201708724. EMBO Mol Med. 2018. PMID: 29666146 Free PMC article.
286 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page